DFTX Definium Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: late-stage clinical biopharma developing psychedelics-based treatments for brain health disorders
• • New emphasis on Phase 3 trials for DT120 ODT targeting GAD and MDD; initiated DT402 Phase 2a trial for autism spectrum disorder in late 2025
• • Strategic shift: rebranded from MindMed to Definium Therapeutics in January 2026, began trading as “DFTX” on Nasdaq
• • Quantitative highlight: DT120 Phase 2b GAD trial showed 7.6-point HAM-A improvement vs placebo (p<0.0004) with 65% response rate sustained to 12 weeks
• • Noteworthy: FDA granted Breakthrough Therapy designation for DT120 in GAD and UK’s MHRA issued Innovation Passport designation in 2024

Risk Factors

• • Regulatory risk: FDA breakthrough designation for DT120 in GAD requires successful Phase 3 trials (Voyage, Panorama) with topline readouts in 2026
• • Geopolitical/macro risk: Clinical trial enrollment and drug supply dependent on U.S. regulations and foreign currency exchange fluctuations affecting expenses
• • Operational risk: Dependence on contract research and manufacturing organizations for clinical trials and cGMP-compliant product supply
• • Competitive risk: Psychedelic drug market includes competitors developing alternative therapies for brain health disorders (no named competitor disclosed)
• • Financial risk: $411.6M cash as of Dec 31, 2025, expected funding into 2028, but reliance on future equity/debt raises could dilute shareholders or impose restrictive covenants

Management Discussion & Analysis

• • No revenue or profitability data disclosed in the provided MD&A excerpt
• • No segment performance or financial results reported
• • No cash flow, capital allocation, buybacks, dividends, or capex information included
• • Forward-looking statements mentioned with general risk disclosure but no specific guidance or outlook

What are the latest DFTX SEC filings in 2026?

Definium Therapeutics, Inc. (DFTX) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on June 24, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did DFTX file its most recent 10-K annual report?

Definium Therapeutics, Inc. (DFTX) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view DFTX 10-Q quarterly reports?

Definium Therapeutics, Inc. (DFTX)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every DFTX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has DFTX filed recently?

Definium Therapeutics, Inc. (DFTX)'s most recent 8-K was filed on June 24, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find DFTX insider trading activity (Form 4)?

SignalX aggregates every DFTX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does DFTX file with the SEC?

Definium Therapeutics, Inc. (DFTX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DFTX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Definium Therapeutics, Inc. (DFTX).

What is DFTX's SEC CIK number?

Definium Therapeutics, Inc. (DFTX)'s SEC CIK (Central Index Key) number is 1813814. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1813814 to look up all DFTX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find DFTX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Definium Therapeutics, Inc. (DFTX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.